Clever Leaves Intrinsic Stock Value – Hypera Pharma and Clever Leaves Join Forces to Expand CBD Availability in Brazil
April 19, 2023
Trending News ☀️
Hypera Pharma and Clever Leaves ($NASDAQ:CLVR) have recently joined forces to increase the availability of Cannabidiol (CBD) products in Brazil. Clever Leaves is a leading global supplier and manufacturer of cannabis compounds, specializing in the cultivation and extraction of hemp and cannabis-based products. The partnership marks a significant step forward for Clever Leaves, allowing them to capitalize on Hypera Pharma’s expertise and resources as they look to increase their presence in the Brazilian market. This strategic alliance is expected to provide Clever Leaves with a comprehensive portfolio of products and services, including access to key distribution channels and support for innovation, marketing, and regulatory affairs in Brazil.
In addition to increased access to CBD products, both companies hope that their joint effort will contribute to the development and growth of the Brazilian medical cannabis industry. This partnership is an important milestone for Clever Leaves, and one that presents an opportunity to further expand their reach in the region. With Hypera Pharma at its side, Clever Leaves is well-positioned to continue its mission of providing high-quality CBD products to consumers across Brazil.
Stock Price
Following the news, the Nasdaq-listed stock of CLEVER LEAVES opened at $0.3 and closed at the same price. The joint venture between Hypera Pharma and Clever Leaves is expected to bring CBD-based products to a wider range of Brazilian consumers, thanks to Hypera’s established presence in the country’s pharmaceutical market. The partnership will promote increased access and availability of CBD products that have been proven beneficial for a variety of medical conditions, including anxiety, depression, and chronic pain. The team at Clever Leaves aims to leverage their expertise in product development and regulatory compliance to ensure that their products are safely accessible to the Brazilian market.
In addition, the company is looking to expand their distribution network in order to improve product availability in select regions. The partnership between Hypera Pharma and Clever Leaves marks an important step forward for the emergence of CBD-based products in Brazil, with the potential to positively impact millions of users around the country. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Clever Leaves. More…
| Total Revenues | Net Income | Net Margin |
| 17.8 | -66.17 | -164.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Clever Leaves. More…
| Operations | Investing | Financing |
| -29.07 | 1.19 | 3.29 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Clever Leaves. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 52.1 | 11.69 | 1.58 |
Key Ratios Snapshot
Some of the financial key ratios for Clever Leaves are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 31.5% | – | -391.9% |
| FCF Margin | ROE | ROA |
| -170.6% | -79.3% | -83.7% |
Analysis – Clever Leaves Intrinsic Stock Value
At GoodWhale, we have analyzed the fundamentals of CLEVER LEAVES to help investors decide whether to invest in this company. Our proprietary Valuation Line shows that the intrinsic value of CLEVER LEAVES share is around $4.7. However, right now the stock is being traded at $0.3, which means it is undervalued by 93.6%. This could be an excellent opportunity for investors who are looking for undervalued stocks. We urge investors to take a closer look at CLEVER LEAVES and determine whether it is a stock worth investing in. More…
Peers
Clever Leaves Holdings Inc is an emerging player in the cannabis industry. It is the first major international player to enter the scene and compete with established companies such as Bhang Inc, Fiore Cannabis Ltd and Green Thumb Industries Inc. Its focus is on cultivating premium grade cannabis products, providing them to consumers at a competitive price.
– Bhang Inc ($OTCPK:BHNGF)
Bhang Inc is a US-based cannabis company that produces high-quality cannabis products such as edibles, flower, concentrates, and topicals. The company has achieved impressive financial results, which has led to an impressive market cap of 4.68M as of 2023. Moreover, its Return on Equity (ROE) of 212.6% is indicative of the company’s success in leveraging its assets and generating profits for its shareholders. This impressive ROE is well above the industry average, and has helped Bhang Inc’s stock to become one of the most sought-after investments in the cannabis sector.
– Fiore Cannabis Ltd ($OTCPK:FIORF)
Fiore Cannabis Ltd is a Canadian-based cannabis company that focuses on the production, distribution, and sale of medicinal cannabis products. The company’s market cap as of 2023 is 315.28k, which is indicative of the company’s growth and success over the years. Furthermore, the company has achieved a Return on Equity of 423.76%, which demonstrates the level of profitability achieved by the company. The company strives to provide premium quality products while adhering to the regulatory standards of their respective markets.
– Green Thumb Industries Inc ($OTCPK:GTBIF)
Green Thumb Industries Inc is a leading cannabis company that operates in 12 states across the US. It has a market cap of 1.88B as of 2023, which is a reflection of its strong position in the industry and its potential for future growth. The company’s Return on Equity (ROE) ratio is 4.81%, which is an indication of its ability to generate profits from its equity capital. Green Thumb Industries Inc’s operations are focused on manufacturing, distributing, and retailing cannabis products to customers across the United States. This diversified approach is helping the company to capture new markets and drive increased revenues.
Summary
Clever Leaves, a leading global medical and wellness cannabis company, has recently announced its partnership with Hypera Pharma, Brazil’s largest pharmaceutical distribution company. This move will enable Clever Leaves to expand its presence in the Brazilian market and capture a larger portion of the growing medical cannabis industry. The partnership will allow Hypera Pharma to distribute Clever Leaves’ products and services throughout Brazil, benefiting from the latter’s expertise in cultivation, extraction, product development, and distribution.
In addition, both companies are set to focus on research and development efforts to further explore the therapeutic potential of cannabis in Brazil. The partnership is a strategic move that is likely to generate significant returns for Clever Leaves’ investors in the near future.
